Dyspnea News and Research

RSS

Dyspnea or dyspnoea or shortness of breath is a debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations.

University of Guelph researcher discovers effective way to treat shortness of breath in heart failure

Shortness of breath is the No.1 complaint of people suffering from heart failure. Now a University of Guelph researcher has discovered its surprising cause - and an effective treatment - in a groundbreaking new study.

17 May 2017

Takeda announces accelerated approval from FDA for new lung cancer treatment

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

28 Apr 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.

3 Apr 2017

FDA approves new maintenance therapy for recurrent cancers

The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.

27 Mar 2017

FDA awards accelerated approval to new ovarian cancer drug

The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer.

19 Dec 2016

Philips to highlight connected sleep and respiratory product portfolio at ERS International Congress 2016

Philips Respironics, a division of Royal Philips, will showcase its portfolio of connected sleep and respiratory solutions at the European Respiratory Society (ERS) International Congress 2016 in London (September 3-7).

6 Sep 2016

Aerobic exercise training reestablishes cardiac protein quality control system in heart failure rats

Aerobic exercise training restored the cardiac protein quality control system in rats showed a study recently published in Journal of Cellular and Molecular Medicine.

8 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Unseen health risks of aortic stenosis: an interview with Dr Shelley Rahman Haley

Aortic stenosis means narrowing of the aortic valve, which is the out flow valve from the left ventricle, the pumping chamber of the heart. This is the valve which opens to allow blood to flood out of the heart and all-round the body.

22 Jun 2016

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.

2 Jun 2016

Minimally important dyspnoea, fatigue changes in PAH patients defined

Researchers say that a change of around 1 unit in Borg dyspnoea or fatigue scores signifies an important change in patients with pulmonary arterial hypertension.

13 Apr 2016

USPSTF does not recommend screening for COPD

The U.S. Preventive Services Task Force does not recommend screening for chronic obstructive pulmonary disease (COPD) in persons who do not have symptoms suggestive of COPD. The report appears in the April 5 issue of JAMA.

6 Apr 2016

New research shows deficiencies in general palliative care for stroke patients

Caregivers are displaying insufficient knowledge of how things are for stroke patients the week before they die - for example, staff have difficulties stating whether the patients had someone with them at their death, or if they were experiencing pain. Care for stroke patients therefore risks becoming worse compared to patients who die from cancer.

13 Mar 2016

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL).

4 Mar 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil).

16 Feb 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.